Original Articles: Bladder Cancer: Intravesical Adjuvant Chemotherapy for Superficial Transitional Cell Bladder Carcinoma: Results of 2 European Organization for Research and Treatment of Cancer Randomized Trials With Mitomycin C and Doxorubicin Comparing Early Versus Delayed Instillations and Short-Term Versus Long-Term Treatment

The Journal of Urology

Volumn 153, Issue 3 SUPPL., 1995, Pages 934-941

  Bouffioux, Ch ^a   Kurth, K H ^a   Bono, A ^a   Oosterlinck, W ^a   Kruger, C Boeken ^a   De Pauw, M ^a   Sylvester, R ^a  

^a OSPEDALE DI CIRCOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; DOXORUBICIN;

ADULT; AGED; ALLERGIC REACTION; ARTICLE; BLADDER CARCINOMA; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DETERIORATION; DOSE RESPONSE; FEMALE; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL; REGIONAL PERFUSION; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; VERTIGO;

ADMINISTRATION, INTRAVESICAL; AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 0028909214     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)67608-0     Document Type: Article

References (35)

1. Quelle chimiotherapie pour quelle tumeur de vessie?
2. Intravesical adjuvant treatment in superficial bladder cancer. A review of the question after 15 years of experience with the EORTC GU Group
3. Adjuvant chemotherapy of superficial transitional cell carcinoma: an EORTC randomized trial comparing doxorubicin hydrochloride, ethoglucid, and TUR-alone
4. The correlation of T1 bladder tumour history with prognosis and follow-up requirements
5. Long-term fate of 90 patients with superficial bladder cancer randomly assigned to receive or not to receive thiotepa
6. Mitomycin instillation to prevent recurrence of superficial bladder carcinoma: results of a controlled, prospective study in 58 patients
7. Experience with intravesical bacillus Calmette-Guerin therapy of superficial bladder tumors
8. Rheinisch Westfalische Technische Hochschulte, Aachen: Natural history and treatment of low and high risk superficial bladder tumors
9. Adriamycin versus BCG in superficial bladder cancer: a Southwest Oncology Group study
10. Bladder tumors invading the lamina propria (stage T1): influence of endovesical BCG therapy on recurrence and progression
11. Long-term versus short-term doxorubicin hydrochloride instillation after transurethral resection of superficial bladder cancer
12. The place of intravesical chemotherapy as defined by the results of prospective randomized studies (substances and treatment schemes)
13. An overview of intravesical therapy for superficial bladder tumors
14. Implantation of transitional tumor cells on the cauterized murine urothelial surface
15. Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma
16. Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma
17. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in stage Ta,T1 papillary carcinoma of the bladder
18. Bladder tumors and associated proliferative mucosal lesions
19. The association of urothelial atypism with neoplasia: its importance in treatment and prognosis
20. The site of recurrence of non-infiltrating bladder tumors
21. 'Normal' urothelium in patients with bladder cancer: a preliminary report from the National Bladder Cancer Collaborative Group
22. Intravesical chemotherapy for superficial bladder tumors
23. Intravesical adriamycin
24. Intravesical chemotherapy for carcinoma of the bladder: duration of the treatment course
25. Recurrence prophylaxis in superficial bladder tumors with adriamycin
26. Single dose intravesical epodyl after TUR of Ta TCC bladder carcinoma
27. Influence of thiotepa and doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial
28. Early intensive adjuvant ADM in superficial transitional cell carcinoma of the bladder: further report
29. The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer An MRC study MRC Working Party on Urological Cancer
30. Long-term mitomycin C instillation after transurethral resection of superficial bladder carcinoma: influence on recurrence, progression and survival
31. Comparison of different schedules of cytostatic intravesical instillations in patients with superficial bladder carcinoma: final evaluation of a prospective multicenter study with 419 patients
32. A prospective randomized trial of maintenance versus nonmaintenance bacillus Calmette-Guerin therapy of superficial bladder cancer
33. Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial
34. Maintenance BCG immunotherapy of superficial bladder cancer: a randomized prospective Southwest Oncology Group study